Urovant Sciences — Jefferies Virtual Health Care Conference 2020
27 slides from Urovant Sciences's conference presentation, Jun 2, 2020
Slide 1: Jefferies Virtual Health Care Conference
UROVANT SCIENCES Jefferies Virtual Health Care Conference June 2, 2020 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, including without limitation, statements related to: our plans to file for approval of vibegron with the FDA, and the timing of such filing and the likelihood of FDA approval; our ability to successfully develop Vibegr
Slide 3: Investment Highlights
1. Subject to the approval by the FDA, including FDA approval of the inclusion of urgency data, rapid onset of action data and a single convenient once-daily dose in the label Investment Highlights UROVANT Vibegron: NDA accepted March 2020 Positive EMPOWUR Phase 3 results announced in March 2019 PDU
Slide 4: Urovant Pipeline
Urovant Pipeline Development and Acquisition of Differentiated Treatments Supports Vision of Becoming a Leading Urology Company DRUG CANDIDATE INDICATION PHASE 1 PHASE 2 PHASE 3 UPCOMING MILESTONE vibegron Overactive Bladder (OAB) PDUFA date December 26, 2020 OAB in Men with BPH Phase 3 top-line dat
Slide 5: Vibegron Clinical Data and Development
VIBEGRON CLINICAL DATA AND DEVELOPMENT
Slide 6: Extensive Clinical Development Program
Extensive Clinical Development Program Three successful, placebo-controlled studies completed in over 4,000 patients achieving all primary and secondary endpoints Robust clinical pharmacology package (21 studies complete) Long-term toxicity and carcinogenicity studies complete In-licensed from Merck
Slide 7: EMPOWUR Results: Strong Efficacy Across All OAB Endpoints
EMPOWUR Results: Vibegron Demonstrated Strong Efficacy Across All OAB Endpoints Week 12 LS Mean Change from Baseline (Placebo-Adjusted) Endpoint Vibegron n p-value UUI Episodes2 -0.6 383 <0.0001 Micturitions2 -0.5 492 <0.001 Urgency Episodes3 -0.7 492 0.0020 Total Incontinence Episodes3 -0.7 383 <0.
Slide 8: Rapid Onset and Sustained Benefit in Phase 3 Trial
Rapid Onset and Sustained Benefit in Phase 3 Trial Table 14.2.2.1.2, Full Analysis Set for Incontinence, CFB Least squares mean Covariates included in the mixed model for repeated measures are study visit, sex, region, baseline number of UUI, and treatment by study visit interaction Change in Averag
Slide 9: >50% of Patients Achieved ≥75% Reduction in UUI Episodes at Week 12
>50% of Patients Achieved ≥75% Reduction in UUI Episodes at Week 12 P-value is active vs placebo NS1 P < 0.001 P < 0.05 P < 0.05 1. P-values for the difference in proportions between active and placebo were calculated using the Cochran-Mantel-Haenszel risk difference estimate stratified by OAB Type
Slide 10: Vibegron was Well Tolerated
Vibegron was Well Tolerated Table 14.3.1.15, Safety Analysis Set. Represents number of patients. Vibegron has not demonstrated a QTc signal at any dose, including 400 mg (highest tested dose) Completed ambulatory blood pressure study with no statistically significant increase in daytime ambulatory s
Slide 11: Vibegron: Potential for Category-Defining Differentiation in OAB
Vibegron: Significant Potential For Category-Defining Differentiation1 in OAB vibegron2 ACh mirabegron Rapid onset of efficacy (2 weeks) Potential efficacy claim for urgency3 Potential broader efficacy claims No CYP2D6 drug-drug interactions Some Single convenient crushable dose4 No known dementia r
Slide 12: OAB Market and Vibegron Commercial Strategy
OAB MARKET AND VIBEGRON COMMERCIAL STRATEGY
Slide 13: Large Market
Large Market ~14 million patients discuss symptoms with a physician2 ~3.3 million patients on prescription therapy3 More than 30 million Americans over 40 years old suffer from bothersome symptoms of OAB1 1. Coyne et al., EpiLUTS 2007 2. Benner et al., J Urol, 2009 3. BIQVIA (IMS) New to Brand Data
Slide 14: β3 Agonist (Mirabegron) Is Gaining U.S. OAB Market Share
β3 Agonist (Mirabegron) Is Gaining U.S. OAB Market Share 1. IQVIA Launch Edition October 2012 through March 2020 2. Astellas reported projected net sales of mirabegron in the Americas of $821M for FY 2019 , ended March 31, 2020 (vs. $728M FY 2018) 3. Urovant analysis and estimate based on mirabegron
Slide 15: Goal: Establish Vibegron as the OAB Brand of Choice
Goal: Establish Vibegron as the OAB Brand of Choice Start with a targeted effort with high prescribing PCPs Ensure broad payor coverage Activate patients to request vibegron Deploy a fully scaled, best-in-class sales force in Urology and Long-Term Care Key Elements of Commercial Strategy Explore co-
Slide 16: Urologists, LTC, High Prescribing PCPs Write >50% of OAB Prescriptions
Urologists, LTC, High Prescribing PCPs Write >50% of OAB Prescriptions Other 13% Long-Term Care 17% Urologist 20% NPPA 16% OB/GYN 5% PCP 29% OAB Rx 2018 Volume by Specialty1 Urologists, LTC, and High Prescribing PCPs account for >50% of all OAB prescriptions Urologists prescribe 30% of all β3s Urolo
Slide 17: Formulary Acceptance will be Key to Vibegron Success
Formulary Acceptance will be Key to Vibegron Success β3 category enjoys wide payor coverage under Medicare Part D and commercial plans Establishing market access team with deep experience in Urology to obtain formulary coverage 1. IMS PayerTrak Dec 2018 2. IQVIA (IMS) NPA data ending Dec 2018. TRx b
Slide 18: Vibegron Could Potentially Lower Overall Costs of Care
Vibegron Could Potentially Lower Overall Costs of Care Annual Direct Medical Costs for OAB Patients are >2.5X HIGHER Than Non-OAB Patients1 Admission to a nursing facility: 2.0x greater for incontinent women2 3.2x greater for incontinent men2 19%-50% of OAB patients experienced a fall over a 1-year
Slide 19: Growth Opportunities
GROWTH OPPORTUNITIES DO NOT DUPLICATE, DETAIL, DISTRIBUTE, TRANSMIT, FORWARD, ORUSE IN ANY PROMOTIONALMANNER
Slide 20: IBS-Associated Pain and OAB in Men with BPH Lifecycle Opportunities
IBS-Associated Pain and OAB in Men with BPH Represent Lifecycle Opportunities with Significant Market Potential 40 million Men aged 50 – 80 years old with BPH >4 million Treated BPH patients in the U.S. OAB in Men with BPH > 2 million U.S. BPH patients with co-morbid OAB IBS population based upon: 1
Slide 21: Gene Therapy Overview: URO-902
Gene Therapy Overview: URO-902 Market Overview Potential to address an unmet need for OAB patients who have failed oral pharmacological therapies and are concerned with potential urinary retention after BOTOX or any “toxin” effect or surgical intervention Currently, there are no FDA-approved gene th
Slide 22: Urovant Sciences Milestones
Urovant Sciences Milestones 2020FDA acceptance of vibegron NDA Preparing for the successful launch of vibegron Further build out commercial leadership team Top-line results of vibegron trial in IBS-associated pain URO-902 complete phase 2a cohort 1 enrollment 2H 2020 PDUFA for vibegron in OAB ü 2021
Slide 23: Investment Highlights
1. Subject to the approval by the FDA, including FDA approval of the inclusion of urgency data, rapid onset of action data and a single convenient once-daily dose in the label Investment Highlights UROVANT Vision: Become A Leading Urology Specialty Company Vibegron: NDA accepted March 2020 Positive
Slide 24: Appendix
APPENDIX DO NOT DUPLICATE, DETAIL, DISTRIBUTE, TRANSMIT, FORWARD, ORUSE IN ANY PROMOTIONALMANNER
Slide 25: OAB+BPH: URO-901-3005 Phase 3
OAB+BPH: URO-901-3005 Phase 3 POPULATION Men with OAB and BPH DURATION 12-week primary efficacy treatment period; 24-week efficacy and safety period plus 6-month extension KEY ENDPOINTS Co-primary endpoints: Change from baseline in daily micturitions (urination) and urgency Key secondary endpoint: N
Slide 26: IBS Associated Pain: URO-901-2001 Phase 2a
IBS Associated Pain: URO-901-2001 Phase 2a POPULATION Women with IBS with predominantly diarrhea (IBS-D) or mixed episodes of diarrhea and constipation (IBS-M) DURATION 12-week primary efficacy treatment period; total observation period 14 weeks (includes 2-week safety follow-up) KEY ENDPOINTS Prima
Slide 27: Gene Therapy OAB: URO-902-2001 Phase 2a Proof-of-Concept Study
Gene Therapy OAB: URO-902-2001 Exploratory Phase 2a Proof-of-Concept Study POPULATION Women 40-79 years old with OAB and urge urinary incontinence (non-childbearing potential) DURATION 12-week primary efficacy treatment period; total observation period of 48 weeks KEY ENDPOINTS Change at week 12 in
Urovant Sciences — Jefferies Virtual Health Care Conference 2020 on 6ix